metyrosine-derivative + methoxsalen + phenytoin + sirolimus

This is a combination of four pharmacologically active agents, each with distinct mechanisms of action: - **Metyrosine-derivative** is an inhibitor of tyrosine hydroxylase, the rate-limiting enzyme in catecholamine biosynthesis. It reduces endogenous levels of catecholamines (dopamine, norepinephrine, epinephrine), primarily used to manage pheochromocytoma by lowering blood pressure and reducing hypertensive attacks[1][2][4]. - **Methoxsalen** is a psoralen derivative that intercalates into DNA and, upon activation by UVA light (PUVA therapy), forms cross-links that inhibit DNA synthesis. It is mainly used for skin disorders such as psoriasis and vitiligo. - **Phenytoin** is an anticonvulsant that stabilizes neuronal membranes by blocking voltage-gated sodium channels in their inactive state. This suppresses high-frequency repetitive firing in neurons and prevents seizure propagation[6]. - **Sirolimus** (also known as rapamycin) is an mTOR inhibitor with immunosuppressive properties, commonly used to prevent organ transplant rejection. There are no known approved pharmaceutical products or clinical trials combining all four agents together; this appears to be a hypothetical or research-stage multi-drug regimen.

Brand names

SM-88SM88SM 88

Other names

SM-88SM88SM 88racemetyrosine/methoxsalen/phenytoin/sirolimus